α-cyano-β-dimethylaminocrotonamide | 120651-05-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 乙烯基酰胺
• 英文名称: α-cyano-β-dimethylaminocrotonamide
• 英文别名: 2-cyano-3-(dimethylamino)but-2-enamide；2-cyano-3-dimethylaminocrotonamide；(Z)-2-cyano-3-(dimethylamino)but-2-enamide；2-cyano-3-(dimethylamino)-2-butenamide
• CAS: 120651-05-0
• 化学式: C₇H₁₁N₃O
• 分子量: 153.184
• InChiKey: CPNKUDCDGKOECR-WAYWQWQTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  α-cyano-β-dimethylaminocrotonamide 在 水 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 6.0h， 生成 3-cyano-4-phenylamino-1,2-dihydropyridin-2-one
  参考文献：
  名称：

  Synthesis and hydrolytic cleavage of 1-aryl-5-cyano-6-(2-dimethylaminovinyl)-4-oxo(thioxo)-1,4-dihydropyrimidines

  摘要：

  1-Aryl-5-cyano-6-(2-dimethylaminovinyl)-4-oxo-1,4-dihydropyrimidines and their 4-thioxo analogs, which were prepared in three steps from cyanoacetamide and cyanothioacetamide, respectively, were subjected to hydrolysis. In aqueous AcOH, hydrolysis of N-(dimethylaminomethylene)-2-cyano-5-dimethylamino-2,4-pentadieneamide derivatives containing amino groups at position 3 afforded formylpyridones. The reaction of 2-cyano-3-dimethylaminothiocrotonamide with DMF dimethyl acetal gave rise to 3-cyano-4-dimethylamino-2-methylthiopyridine.

  DOI：

  10.1023/b:rucb.0000037857.07190.75
• 作为产物：
  描述：

  1,1-二甲氧基-N,N-二甲基乙胺 、 氰乙酰胺 以 乙醇 为溶剂， 反应 2.5h， 生成 α-cyano-β-dimethylaminocrotonamide 、 α-cyano-β-dimethylaminocrotonamide
  参考文献：
  名称：

  [EN] NEW TRPA1 ANTAGONISTS
  [FR] NOUVEAUX ANTAGONISTES DE TRPA1

  摘要：

  本发明涉及式(I)的化合物，以及制备这种化合物的方法，以及它们在治疗通过TRPA1通道抑制或拮抗可改善的病理状况或疾病中的用途。

  公开号：

  WO2017060488A1

文献信息

• mGluR1 antagonists as therapeutic agents
  申请人：Matasi J. Julius

  公开号：US20060009477A1

  公开（公告）日：2006-01-12

  In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J 1 -J 4 , X, and R 1 —R 5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.

  在其多种实施方式中，本发明提供了式I的三环化合物（其中J1-J4、X和R1—R5如本文所定义）作为代谢型谷氨酸受体（mGluR）拮抗剂，特别是作为选择性代谢型谷氨酸受体1拮抗剂，含有该化合物的药物组合物，以及使用该化合物和组合物治疗与代谢型谷氨酸受体（例如mGluR1）相关的疾病的方法，例如疼痛、偏头痛、焦虑、尿失禁和阿尔茨海默病等神经退行性疾病。
• [EN] RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS INHIBITEURS DE RAF ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2011025940A1

  公开（公告）日：2011-03-03

  Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  公式I的化合物对于抑制Raf激酶是有用的。本文披露了利用公式I的化合物及其立体异构体、互变异构体、前药和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• Substituted 3-and 5-formylpyridin-2-ones in the synthesis of 1-aryl-1, 6-naphthyridinone derivatives
  作者：M. I. Medvedeva、N. Z. Tugusheva、L. M. Alekseeva、M. I. Evstratova、S. S. Kiselev、V. V. Chernyshev、G. V. Avramenko、V. G. Granik

  DOI：10.1007/s11172-009-0325-7

  日期：2009.11

  the action of various CH acids. A new approach to the synthesis of 4-(4-fluoroanilino)-5-formyl-2-oxo-1,2-dihydropyridine-3-carbonitrile using dimethylformamide diisopropylacetal under mild conditions was developed. The comparative reactivity of the formyl group in the reactions of 4-arylamino-5-formyl-2-oxo-1,2-dihydropyridine-3-carbonitriles and in 4-arylamino-2-oxo-1,2-dihydropyridine-3-carb-aldehydes

  新的 1-aryl-6-[2-(二甲基氨基)vinyl]4-oxo-1,4-dihydropyrimidine-5-carbonitriles 和 4-arylamino-2-oxo-1,2-dihydropyridine-3-carbonitriles 含吸电子苯环中的取代基由烯氨基酰胺和二甲基甲酰胺二烷基缩醛合成。研究了反应中各种二甲基甲酰胺缩醛对3-(4-氯-苯胺基)-2-氰基-5-(二甲氨基)五-2,4-二烯酸N-(二甲氨基)亚甲基酰胺产率的影响这些缩醛与 3-(4-氯苯胺)-2-氰基巴豆酰胺。新的 4-arylamino-5-formyl-2-oxo-1,2-dihydropyridine-3-carbonitriles 和 4-arylamino-2-oxo-1,2-dihydropyridine-3-carbaldehydes 在苯环中含有吸电子取代基合成的。后一种化合物被转化为新的取代
• Fused tricyclic mGIuR1 antagonists as therapeutic agents
  申请人：Bennett E. Chad

  公开号：US20070072864A1

  公开（公告）日：2007-03-29

  In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J 1 -J 3 , X, Z, and R 1 , R 3 , and R 4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.

  在其许多实施例中，本发明提供了公式I的三环化合物（其中J1-J3、X、Z和R1、R3和R4如本文所定义）作为代谢型谷氨酸受体（mGluR）拮抗剂，特别作为选择性代谢型谷氨酸受体1拮抗剂，含有该化合物的药物组合物，以及使用该化合物和组合物治疗与代谢型谷氨酸受体（例如mGluR1）相关的疾病的方法，例如疼痛、偏头痛、焦虑、尿失禁和阿尔茨海默病等神经退行性疾病。
• Synthesis and functionalization of 4-arylamino-2-pyridone derivatives
  作者：N. Z. Tugusheva、L. M. Alekseeva、A. S. Shashkov、V. V. Chernyshev、V. G. Granik

  DOI：10.1007/s11172-006-0443-4

  日期：2006.8

  New approaches to the synthesis of the previously unknown pyrimidine, 4-amino-2-pyridone, and 4-aminopyridine derivatives were developed based on the reactions of enaminoamides with dimethylformamide dimethyl acetal. New structural modifications of 4-amino-2-pyridone derivatives were performed. Numerous compounds of this type, which are of interest for biological studies, were prepared.

  根据烯酰胺与二甲基甲酰胺二甲基缩醛的反应，开发了合成以前未知的嘧啶、4-氨基-2-吡啶酮和 4-氨基吡啶衍生物的新方法。对 4-氨基-2-吡啶酮衍生物进行了新的结构改造。制备出了许多对生物研究有意义的此类化合物。